The CKS1B antibody targets the CKS1B protein, a member of the CDC28 protein kinase regulatory subunit (CKS) family. CKS1B plays a critical role in cell cycle regulation, particularly in the transition from G1 to S phase by interacting with cyclin-dependent kinases (CDKs). It facilitates CDK substrate recognition and phosphorylation, influencing processes like DNA replication and checkpoint control. Dysregulation of CKS1B has been linked to tumorigenesis, with overexpression observed in various cancers, including multiple myeloma, breast cancer, and lung carcinoma. This overexpression is often associated with poor prognosis, making CKS1B a potential biomarker for disease progression and therapeutic targeting. The CKS1B antibody is widely used in research to study protein expression patterns, subcellular localization (nuclear/cytoplasmic), and functional roles in cancer biology. It is employed in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate its involvement in cell cycle anomalies and oncogenic pathways. Additionally, studies explore its utility in developing CDK-targeted therapies or as a diagnostic tool for malignancies. The antibody's specificity for CKS1B (distinct from the homologous CKS1A) ensures accurate detection in experimental models, aiding mechanistic insights into cell cycle dysregulation and cancer therapeutics.